Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG.

Eur Arch Psychiatry Clin Neurosci. 2019 Jan 31. doi: 10.1007/s00406-019-00982-6. [Epub ahead of print] Review.

PMID:
30706171
2.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
3.

Death by self-mutilation after oral cannabis consumption.

Delteil C, Sastre C, Piercecchi MD, Faget-Agius C, Deveaux M, Kintz P, Devooght MA, Leonetti G, Bartoli C, Pélissier-Alicot AL.

Leg Med (Tokyo). 2018 Jan;30:5-9. doi: 10.1016/j.legalmed.2017.10.010. Epub 2017 Nov 2.

PMID:
29125965
4.

Cannabidiol inhibits priming-induced reinstatement of methamphetamine in REM sleep deprived rats.

Karimi-Haghighi S, Haghparast A.

Prog Neuropsychopharmacol Biol Psychiatry. 2018 Mar 2;82:307-313. doi: 10.1016/j.pnpbp.2017.08.022. Epub 2017 Sep 1.

PMID:
28870635
5.

The Endocannabinoid System in the Retina: From Physiology to Practical and Therapeutic Applications.

Schwitzer T, Schwan R, Angioi-Duprez K, Giersch A, Laprevote V.

Neural Plast. 2016;2016:2916732. doi: 10.1155/2016/2916732. Epub 2016 Jan 6. Review.

6.

Effect of cannabidiol on sleep disruption induced by the repeated combination tests consisting of open field and elevated plus-maze in rats.

Hsiao YT, Yi PL, Li CL, Chang FC.

Neuropharmacology. 2012 Jan;62(1):373-84. doi: 10.1016/j.neuropharm.2011.08.013. Epub 2011 Aug 16.

PMID:
21867717
7.

Neuroprotective effects of cannabidiol in endotoxin-induced uveitis: critical role of p38 MAPK activation.

El-Remessy AB, Tang Y, Zhu G, Matragoon S, Khalifa Y, Liu EK, Liu JY, Hanson E, Mian S, Fatteh N, Liou GI.

Mol Vis. 2008;14:2190-203. Epub 2008 Dec 3. Retraction in: Mol Vis. 2014;20:1227.

8.

Effect of sublingual application of cannabinoids on intraocular pressure: a pilot study.

Tomida I, Azuara-Blanco A, House H, Flint M, Pertwee RG, Robson PJ.

J Glaucoma. 2006 Oct;15(5):349-53.

PMID:
16988594
9.

Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats.

Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R.

FEBS Lett. 2006 Aug 7;580(18):4337-45. Epub 2006 Jul 10.

10.

Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes.

El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI.

Am J Pathol. 2006 Jan;168(1):235-44.

11.

Cannabinoids in clinical practice.

Williamson EM, Evans FJ.

Drugs. 2000 Dec;60(6):1303-14. Review.

PMID:
11152013
12.

Effects of cannabidiol in animal models predictive of antipsychotic activity.

Zuardi AW, Rodrigues JA, Cunha JM.

Psychopharmacology (Berl). 1991;104(2):260-4.

PMID:
1678894
13.
14.

Cannabinoids in glaucoma: a primary screening procedure.

Elsohly MA, Harland E, Murphy JC, Wirth P, Waller CW.

J Clin Pharmacol. 1981 Aug-Sep;21(S1):472S-478S.

PMID:
6271842
15.

Toward drugs derived from cannabis.

Mechoulam R, Carlini EA.

Naturwissenschaften. 1978 Apr;65(4):174-9. Review.

PMID:
351429
16.

Chemical basis of hashish activity.

Mechoulam R, Shani A, Edery H, Grunfeld Y.

Science. 1970 Aug 7;169(3945):611-2.

PMID:
4987683

Supplemental Content

Loading ...
Support Center